Treatment of Distal Ulcerative Colitis with Nonsystemic Corticosteroid Enemas

References

• Reynolds P D, Hunter J O. Pharmacotherapy of inflammatory bowel disease. Dig Dis 1993; 11: 334–42
   PubMed Web of Science ®Google Scholar
• Jewell D P. Improved understanding of IBD: a pathway to a more effective management. Res Clin Forums 1993; 15: 101–3
   Google Scholar
• Campieri M, Gionchetti P, Belluzzi A, Brignola C, Miglioli M, Barbara L. Medical treatment of inflammatory bowel disease. Curr Opin Gastroenterol 1992; 8: 663–75
   Web of Science ®Google Scholar
• Svartz N. The treatment of ulcerative colitis. Gastroenterology 1954; 26: 26–8
   PubMed Web of Science ®Google Scholar
• Miner P, Hanauer S, Robinson M, Schwartz J, Arora S, Pentasa U C. Maintenance Study Group. Safety and efficacy of controlled‐release mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sci 1995; 40: 296–304
   PubMed Web of Science ®Google Scholar
• Peppercorn M A. Advances in drug therapy for inflammatory bowel disease. Ann Intern Med 1990; 112: 50–60
   PubMed Web of Science ®Google Scholar
• Lichtiger S, Present D H, Kornbluth A, Gelernt J, Bauer J, Galler G, et al. Cyclosporin in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841–5
   PubMed Web of Science ®Google Scholar
• Carpani de Kaski M, Hodgson H J. Rolling review: inflammatory bowel disease. Aliment Pharmacol Ther 1993; 7: 567–79
   PubMedGoogle Scholar
• Brattsand R L. Steroid development: a case of enhanced selectivity for the bowel wall. Res Clin Forums 1993; 15/5: 17–33
   Google Scholar
• Schleimer R P, Derse C P, Friedman B, Gillis S, Plaut M, Lichtenstein L M, et al. Regulation of human basophil mediator release by cytokines. J Immunol 1989; 143: 1310–7
   PubMed Web of Science ®Google Scholar
• Flower R J, Blackwell G J. Anti‐inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 1979; 278: 456–9
   PubMed Web of Science ®Google Scholar
• Lauritsen K, Lauresen L S, Bukhavve K, Rask‐Madsen J. In vivo effects of orally administered prednisolone on prostaglandin and leucotriene production in ulcerative colitis. Gut 1987; 28: 1095–9
   PubMed Web of Science ®Google Scholar
• Truelove S C, Witts L J. Cortisone in ulcerative colitis. Preliminary report on a therapeutic trial. Br Med J 1954; 2: 375–8
   PubMed Web of Science ®Google Scholar
• Truelove S C, Witts L J. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955; 2: 1041–8
   PubMed Web of Science ®Google Scholar
• Swartz S L, Dluhy R G. Corticosteroids: clinical pharmacology and therapeutic use. Drugs 1978; 16: 238–55
   PubMed Web of Science ®Google Scholar
• Lindmark B. Short‐ and long‐term steroid sise effects: the importance for patients with inflammatory bowel disease. Res Clin Forums 1993; 15: 35–41
   Google Scholar
• Kusunoki M, Möeslein G, Shoji Y, Fujita S, Yanagi H, Sakanoue Y, et al. Steroid complications in patients with ulcerative colitis. Dis Colon Rectum 1992; 35: 1003–9
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Damkjaer Nielsen M, Andersen B, Andersen P, Foged N, Fuglsang G, et al. Adrenal function in children with bronchial asthma treated with beclomethasone dipropionate or budesonide. J Allergy Clin Immunol 1988; 81: 1088–95
   PubMed Web of Science ®Google Scholar
• Truelove S C. Treatment of ulcerative colitis with local hydrocortisone. Br Med J 1956; 2: 1267–72
   PubMedGoogle Scholar
• Truelove S C. Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium. Br Med J 1957; 1: 1437–43
   PubMedGoogle Scholar
• Matts S GF. Local treatment of ulcerative colitis with prednisolone‐21‐phosphate enemata. Lancet 1960; 1: 517–9
   Web of Science ®Google Scholar
• Matts S GF. Intrarectal treatment of 100 cases of ulcerative colitis with prednisolone‐21‐phosphate enemata. Br Med J 1961; 1: 165–8
   PubMedGoogle Scholar
• Matts S G, Wharton B A, Kelleher J, Walters G. Adrenal cortical and pituitary function after intrarectal steroid therapy. Br Med J 1963; 2: 24–6
   PubMedGoogle Scholar
• Hamilton I, Pinder I F, Dickinson R J, Ruddell W SJ, Dixon M F, Axon A TR. A comparison of prednisolone enemas with low‐dose oral prednisolone in the treatment of acute distal ulcerative colitis. Dis Colon Rectum 1984; 27: 701–2
   PubMed Web of Science ®Google Scholar
• Luman W, Gray R S, Pendek R, Palmer K R. Prednisolone metasulphobenzoate foam retention enemas suppress the hypothalamo‐pituitary‐adrenal axis. Aliment Pharmacol Ther 1994; 8: 255–8
   PubMed Web of Science ®Google Scholar
• Peña A S. A comparative review of available rectal steroids in the treatment of distal disease. Res Clin Forums 1993; 15: 57–64
   Google Scholar
• Kumana C R, Seaton T, Meghji M, Castelli M, Benson R, Sivakumaran T. Beclomethasone dipropionate enemas for treating inflammatory bowel disease without producing Cushing's syndrome or hypothalamic pituitary adrenal suppression. Lancet 1982; 1: 579–83
   PubMed Web of Science ®Google Scholar
• Van der Heide H, van der Brandt‐Grädel V, Tytgat G NJ, Endert E, Wiltink E H, Schipper M E, et al. Comparison of beclomethasone dipropionate and prednisolone‐21‐phosphate enemas in the treatment of ulcerative proctitis. J Clin Gastroenterol 1988; 10: 169–72
   PubMed Web of Science ®Google Scholar
• Jewell D P, Phil D. Corticosteroids for the management of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 1989; 18: 21–34
   PubMed Web of Science ®Google Scholar
• Mulder C JJ, Endert E, van der Heyde H, Houthoff H J, Wiersinga W, Wiltink E H, et al. Comparison of beclomethasone dipropionate (2 and 3 mg) and prednisolone‐sodium phosphate enema (30 mg) in the treatment of distal ulcerative colitis. Neth J Med 1989; 35: 18–24
   PubMed Web of Science ®Google Scholar
• Bansky G, Buhler H, Stamm B, Häcki W H, Buchman P. Treatment of distal ulcerative colitis with beclomethasone enemas: high therapeutic efficacy without endocrine side effects. Dis Colon Rectum 1987; 30: 288–92
   PubMed Web of Science ®Google Scholar
• Hanauer S B, Kirsner J B, Barrett W E. The treatment of left‐sided ulcerative colitis with tixocortol pivalate. Gastroenterology 1986; 90: 1449A
   Google Scholar
• Karp L C, Targan S R. New enema treatments for inflammatory bowel disease. Dig Dis Sci 1988; 33: 85S–7S
   Web of Science ®Google Scholar
• Larochelle P, Du Souich P, Bolte E, Lelorier J, Goyer R. Tixocortol pivalate, a corticosteroid with no systemic glucocorticosteroid effect after oral, intrarectal, and intranasal application. Clin Pharmacol Ther 1983; 3: 343–50
   Google Scholar
• Hanauer S B. Clinical experience with tixocortol pivalate. Can J Gastroenterol 1988; 2: 156–8
   Google Scholar
• Brattsand R. Overview of newer glucocorticoid preparations for inflammatory bowel disease. Can J Gastroenterol 1990; 4: 407–14
   Google Scholar
• Edsbäcker S, Dahlström K, Conradson T B. Rectal and oral bioavailability of budesonide in man. Hell J Gastroenterol 1992; 5: 75, Suppl
   Google Scholar
• Dahlberg E, Thalen A, Brattsand R, Gustafsson J Å, Johansson U, Roempke K, et al. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16alpha, 17alpha‐acetal‐substituted glucocorticoids. Mol Pharmacol 1984; 25: 70–8
   PubMed Web of Science ®Google Scholar
• Edsbäcker S, Johansson S Å. Correlation between kinetic properties and clinical safety of budesonide enema. Abstract presented at the World Congress of Gastroenterology, SydneyAustralia, August, 26–311990, PD561
   Google Scholar
• Möllmann H W, Tromm A, May B, Barth J, Bigalke C, Derendorf H, et al. Pharmacokinetic evaluation of budesonide enema and suppositories. Gastroenterology 1994; 106: A737
   Web of Science ®Google Scholar
• Danielsson Å, Edsbåcker S, Löfberg R, Nilsson Å, Nyman‐Pantelidis M, Olsson O, et al. Pharmacokinetics of budesonide enema in patients with distal ulcerative colitis or proctitis. Aliment Pharmacol Ther 1993; 7: 401–7
   PubMed Web of Science ®Google Scholar
• Matzen P. Budesonide enema in distal ulcerative colitis. A randomized dose‐response trial with prednisolone enema as positive control. The Danish Budesonide Study Group. Scand J Gastroenterol 1991; 26: 1225–30
   PubMed Web of Science ®Google Scholar
• Hanauer S, Robinson M, the U.S. Budesonide Enema Study Group. Dose ranging study of budesonide enema in active distal ulcerative colitis. Gastroenterology 1995; 108: A833
   Web of Science ®Google Scholar
• Danielsson Å, Löfberg R, Persson T, Salde L, Schiöler R, Suhr O, et al. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol 1992; 27: 9–12
   PubMed Web of Science ®Google Scholar
• Florén C H, Benoni C, Willén R. Histological and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol 1987; 22: 459–62
   PubMed Web of Science ®Google Scholar
• Bayless T, Sninsky C, the U.S. Budesonide Enema Study Group. Budesonide enema is an effective alternative to hydrocortisone enema in active distal ulcerative colitis. Gastroenterology 1995; 108: A778
   Web of Science ®Google Scholar
• Danielsson Å, Hellers G, Lyrenäs E, Löfberg R, Nilsson Å, Olsson O. A controlled randomised trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol 1987; 22: 987–92
   PubMed Web of Science ®Google Scholar
• Porro G B, Prantera C, Campieri M, Petrillo M, Campanini M C, Gionchetti P, et al. Comparative trial of methylprednisolone and budesonide enemas in active distal ulcerative colitis. Eur J Gastroenterol Hepatol 1994; 6: 125–30
   Web of Science ®Google Scholar
• Thomsen O Ö, Andersen T, Langholz E, Löfberg R, Malchow‐Möller A, Matzen P, et al. Lack of adrenal gland suppression with budesonide enema in active distal ulcerative colitis: a prednisolone‐controlled 8‐week study. Eur J Gastroenterol Hepatol 1994; 6: 507–11
   Web of Science ®Google Scholar
• Lamers C, Meijer J, Engels L, Bos L, Van Hogezand R, Driessen W, et al. Comparative study of the topically acting glucocorticosteroid budesonide and 5‐aminosalicylic acid enema therapy of proctitis and proctosigmoiditis. Gastroenterology 1991; 100: A223
   Google Scholar
• Tarpila S, Turunen U, Seppälä K, Aukee S, Pikkarainen P, Elomaa I, et al. Budesonide enema in active haemorrhagic proctitis—a controlled trial against hydrocortisone foam enema. Aliment Pharmacol Ther 1994; 8: 591–5
   PubMed Web of Science ®Google Scholar
• Löfberg R, Östergaard‐Thomsen O, Langholz E, Schiöler R, Danielsson Å, Suhr O, et al. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1994; 8: 623–9
   PubMed Web of Science ®Google Scholar
• Somerville K W, Langman M JS, Kane S P, Macgilchrist A J, Watkinson G, Salmon P. Effect of treatment on symptoms and quality of life in patients with ulcerative colitis: comparative trial of hydrocortisone acetate foam and prednisolone 21‐phosphate enemas. Br Med J 1985; 291: 866
   PubMedGoogle Scholar
• Lemann M, Galian A, Rutgeerts P, Van Heuverzwijn R, Cortot A, Viteau J M, et al. Comparison of budesonide and 5‐aminosalicylic acid enemas in active distal ulcerative colitis. Eur J Hepatol Gastroenterol
   Google Scholar
• Rutgeerts P, Löfberg R, Malchow H, Lamers C, Olaison G, Jewell D, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842–5
   PubMed Web of Science ®Google Scholar
• Greenberg G R, Feagan B G, Martin F, Sutherland L R, Thomson A BR, Williams C N, et al. Oral budesonide for active Crohn's disease. N Engl J Med 1994; 331: 836–41
   PubMed Web of Science ®Google Scholar
• Löfberg R, Danielsson Å, Suhr O, Nilsson Å, Schiöler R, Nyberg A, et al. Oral budesonide versus prednisolone in active extensive and left‐sided ulcerative colitits. A nine week multicenter pilot trial. Gastroenterology 1996; 110: 1713–8
   PubMed Web of Science ®Google Scholar
• Corticosteroids. Martindale the extra pharmacopoeia13th ed., J E.F Reynolds. The Pharmaceutical Press, London 1993; 712–40
   Google Scholar